Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
09 Oct 2016 ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung Lung and other thoracic tumours - Anticancer agents & Biologic therapy
09 Oct 2016 ESMO 2016 Press Release: Pembrolizumab New Option for First Line Treatment of Patients with Advanced Lung Cancer and High PD-L1 Expression Lung and other thoracic tumours
09 Oct 2016 ESMO 2016 Press Release: First-line Pembrolizumab Plus Chemotherapy Significantly Improves Outcomes in Advanced NSCLC Lung and other thoracic tumours
09 Oct 2016 ESMO 2016 Press Release: Ceritinib Provides Longer Progression-free Survival Than Chemotherapy in Phase III Trial of ALK Rearranged Lung Cancer Treatment Lung and other thoracic tumours
09 Oct 2016 ESMO 2016 Press Release: Greater Patient Selection May be Needed for First Line Nivolumab to Improve Progression-free Survival in Advanced Lung Cancer Lung and other thoracic tumours
07 Oct 2016 ESMO 2016 Press Release: Neoadjuvant Immunotherapy Prior to Surgery is Safe and Feasible in Early Lung Cancer Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
29 Sep 2016 FDA Modifies the Dosage Regimen for Currently Approved Indications for Nivolumab Genitourinary cancers - Melanoma and other skin tumours - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
05 Sep 2016 Completion of Rolling Submission of New Drug Application for Brigatinib to the US FDA Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
29 Aug 2016 Latest NICE Medtech Innovation Briefings and Technology Appraisal Guidance Recommendations for Cancer Breast cancer - Genitourinary cancers - Haematologic malignancies - Lung and other thoracic tumours - Gastrointestinal cancers
25 Jul 2016 EMA Recommends Extension of Therapeutic Indications for Crizotinib Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
30 Jun 2016 NICE Issues Technology Appraisal Guidance for Ceritinib Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Jun 2016 EMA Recommends To Extend Indications for Pembrolizumab Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
03 Jun 2016 FDA Approves First Blood Test to Detect EGFR mutations associated with NSCLC Personalised medicine - Lung and other thoracic tumours
30 May 2016 Withdrawal of the EU Marketing Authorisation Application for Rociletinib Lung and other thoracic tumours - Anticancer agents & Biologic therapy
23 May 2016 Unprecedented Progress in the Treatment of NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy